Teva Pharma Financials
| TEVA Stock | USD 12.78 0.40 3.03% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 2.82 | 2.6849 |
|
| |||||
| Current Ratio | 1.68 | 1.0194 |
|
|
The financial analysis of Teva Pharma is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Teva Pharma includes many different criteria found on its balance sheet. For example, investors should never minimize Teva Pharma's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Teva Pharma's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Teva Pharma.
Net Income |
|
With this module, you can analyze Teva financials for your investing period. You should be able to track the changes in Teva Pharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Teva | Select Account or Indicator |
Understanding current and past Teva Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Teva Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Teva Pharma's assets may result in an increase in income on the income statement.
The data published in Teva Pharma's official financial statements usually reflect Teva Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Teva Pharma Industries. For example, before you start analyzing numbers published by Teva accountants, it's critical to develop an understanding of what Teva Pharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Teva Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Teva Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Teva Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Teva Pharma Industries. Please utilize our Beneish M Score to check the likelihood of Teva Pharma's management manipulating its earnings.
Teva Pharma Stock Summary
Teva Pharma competes with Alkermes Plc, Ironwood Pharmaceuticals, Deciphera Pharmaceuticals, Eagle Pharmaceuticals, and Neurocrine Biosciences. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. Teva Pharmaceutical is traded on New York Stock Exchange in the United States.| Foreign Associate | Israel |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | US8816242098 |
| CUSIP | 881624209 |
| Location | Israel |
| Business Address | 124 Dvora HaNevia |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.tevapharm.com |
| Phone | 972 3 914 8213 |
| Currency | USD - US Dollar |
You should never invest in Teva Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Teva Stock, because this is throwing your money away. Analyzing the key information contained in Teva Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Teva Pharma Key Financial Ratios
Generally speaking, Teva Pharma's financial ratios allow both analysts and investors to convert raw data from Teva Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Teva Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Teva Pharma Industries reports annually and quarterly.| Return On Equity | -0.0736 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.28 % |
Teva Pharma Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
| Other Current Liab | 890M | 931M | 903M | 6.0B | 1.1B | 1.6B | |
| Net Debt | 25.4B | 24.2B | 21.3B | 18.8B | 16.9B | 17.8B | |
| Retained Earnings | (7.0B) | (10.9B) | (10.5B) | (12.9B) | (13.5B) | (12.9B) | |
| Cash | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
| Net Receivables | 5.7B | 4.6B | 4.5B | 3.7B | 3.4B | 3.0B | |
| Inventory | 4.4B | 4.4B | 3.8B | 3.8B | 4.0B | 2.4B | |
| Other Current Assets | 434M | 710M | 967M | 549M | 505M | 914.4M | |
| Total Liab | 42.4B | 39.6B | 36.4B | 35.3B | 35.4B | 37.1B | |
| Total Current Assets | 13.5B | 13.0B | 12.6B | 12.1B | 12.5B | 7.7B | |
| Short Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 1.3B | |
| Intangible Assets | 11.2B | 8.9B | 7.5B | 6.3B | 5.4B | 4.7B | |
| Accounts Payable | 1.7B | 1.8B | 1.7B | 1.9B | 2.6B | 2.1B | |
| Other Liab | 3.7B | 3.2B | 3.4B | 4.4B | 5.1B | 5.3B | |
| Other Assets | 2.1B | 1.1B | 1M | (1M) | 1.9B | 950K | |
| Long Term Debt | 24.6B | 22.7B | 21.6B | 19.1B | 18.2B | 12.5B | |
| Good Will | 24.8B | 20.6B | 20.0B | 17.6B | 17.2B | 17.7B | |
| Short Long Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 2.6B | |
| Net Tangible Assets | (22.1B) | (19.5B) | (17.2B) | (16.0B) | (14.4B) | (15.1B) |
Teva Pharma Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Teva Pharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 822M | 963M | 1.1B | 966M | 1.0B | 1.1B | |
| Total Revenue | 16.9B | 16.7B | 15.9B | 14.9B | 15.8B | 9.5B | |
| Gross Profit | 7.5B | 7.7B | 7.6B | 7.0B | 7.6B | 4.8B | |
| Operating Income | (1.6B) | 2.8B | 3.1B | 3.2B | 433M | 732.2M | |
| Ebit | 1.3B | 2.8B | 3.1B | 3.2B | 433M | 411.4M | |
| Ebitda | 3.2B | 4.6B | 4.5B | 4.1B | 433M | 411.4M | |
| Cost Of Revenue | 9.4B | 8.9B | 8.3B | 8.0B | 8.2B | 4.7B | |
| Income Before Tax | (1.3B) | (4.4B) | 658M | (3.1B) | (624M) | (592.8M) | |
| Net Income | (999M) | (4.0B) | 417M | (2.4B) | (559M) | (531.1M) | |
| Income Tax Expense | (278M) | (168M) | 211M | (638M) | (65M) | (61.8M) | |
| Research Development | 1.0B | 997M | 967M | 838M | 953M | 809.2M | |
| Minority Interest | (2M) | (109M) | 39M | 53M | 56M | 74.7M | |
| Tax Provision | (278M) | (168M) | 211M | (638M) | (7M) | (7.4M) | |
| Net Interest Income | (877M) | (963M) | (962M) | (966M) | (1.1B) | (1.1B) |
Teva Pharma Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Teva Pharma Industries. It measures of how well Teva is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Teva Pharma brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Teva had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Teva Pharma has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 271M | 41M | 380M | (163M) | (147M) | (139.7M) | |
| Change In Cash | 734M | 202M | 21M | 636M | 393M | 412.7M | |
| Free Cash Flow | 419M | 638M | 236M | 1.0B | 842M | 1.5B | |
| Depreciation | 1.8B | 416M | 1.6B | 1.3B | 1.2B | 767.4M | |
| Other Non Cash Items | 471M | 6.5B | 714M | 2.4B | 1.1B | 1.6B | |
| Capital Expenditures | 119M | 578M | 562M | 548M | 526M | 486.4M | |
| Net Income | 76M | (4.1B) | 456M | (2.4B) | (615M) | (584.3M) | |
| End Period Cash Flow | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
| Investments | 343M | 67M | 172M | 656M | 968M | 1.0B | |
| Net Borrowings | (1.9B) | (1.9B) | (1.7B) | (1.4B) | (1.2B) | (1.2B) | |
| Change To Netincome | 1.9B | 6.9B | 729M | 1.4B | 1.2B | 1.2B |
Teva Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Teva Pharma's current stock value. Our valuation model uses many indicators to compare Teva Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Teva Pharma competition to find correlations between indicators driving Teva Pharma's intrinsic value. More Info.Teva Pharma Industries is rated fifth in return on equity category among related companies. It is rated fifth in return on asset category among related companies . At present, Teva Pharma's Return On Equity is projected to slightly decrease based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Teva Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Teva Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Teva Pharma's earnings, one of the primary drivers of an investment's value.Teva Pharma Industries Systematic Risk
Teva Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Teva Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifty with a total number of output elements of eleven. The Beta measures systematic risk based on how returns on Teva Pharma Industries correlated with the market. If Beta is less than 0 Teva Pharma generally moves in the opposite direction as compared to the market. If Teva Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Teva Pharma Industries is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Teva Pharma is generally in the same direction as the market. If Beta > 1 Teva Pharma moves generally in the same direction as, but more than the movement of the benchmark.
About Teva Pharma Financials
What exactly are Teva Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Teva Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Teva Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may use each financial statement separately, they are all related. The changes in Teva Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Teva Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Teva Pharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Teva Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Teva has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Teva Pharma's financials are consistent with your investment objective using the following steps:- Review Teva Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Teva Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Teva Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Teva Pharma's stock is overvalued or undervalued.
Teva Pharma Thematic Clasifications
Teva Pharma Industries is part of several thematic ideas from Adviser Favorites to Israel Wall Street. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Teva Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Teva Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Teva Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Teva Pharma April 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Teva Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Teva Pharma Industries. We use our internally-developed statistical techniques to arrive at the intrinsic value of Teva Pharma Industries based on widely used predictive technical indicators. In general, we focus on analyzing Teva Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Teva Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.39 | |||
| Information Ratio | 0.0973 | |||
| Maximum Drawdown | 11.6 | |||
| Value At Risk | (1.98) | |||
| Potential Upside | 3.1 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.